Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier
- 6 December 2006
- journal article
- other
- Published by BMJ in British Journal of Ophthalmology
- Vol. 91 (4) , 505-508
- https://doi.org/10.1136/bjo.2006.107417
Abstract
Purpose: Pathological neovascularisation within the normally avascular cornea is a serious event that can interfere with normal vision. Upregulation of vascular endothelial growth factor (VEGF) has been associated with neovascularisation in the eye, suggesting that maintaining low levels of VEGF is important for corneal avascularity and intact vision. This study aims to determine the expression profile and possible contribution of sVEGFR-1 to the corneal avascular barrier. Design: Experimental case series investigating VEGF and soluble fms-like tyrosine kinase (sFlt) levels in normal and neovascularised human corneas. Participants: Four normal human corneas, five human corneas with alkali burns, three human corneas with aniridia, one with ocular cicatricial pemphigoid and two with interstitial keratitis were examined. Methods: Western blot and immunohistochemical analyses were performed to determine sFlt and VEGF levels in normal and neovascularised human corneas. Immunoprecipitation was utilised to demonstrate sFlt–VEGF binding. Results: Normal human corneas strongly express sFlt in the corneal epithelium and weakly in the corneal stroma close to the limbus. VEGF is bound by sFlt in the normal human cornea. Neovascularised human corneas have greatly reduced expression of sFlt and significantly less VEGF bound by sFlt. Conclusions: sFlt is highly expressed in the human cornea and normally sequesters VEGF.Keywords
This publication has 16 references indexed in Scilit:
- Corneal avascularity is due to soluble VEGF receptor-1Nature, 2006
- Marked inhibition of retinal neovascularization in rats following soluble‐flt‐1 gene transferThe Journal of Gene Medicine, 2004
- Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritisGene Therapy, 2003
- Periocular Gene Transfer ofsFlt-1Suppresses Ocular Neovascularization and Vascular Endothelial Growth Factor-Induced Breakdown of the Blood-Retinal BarrierHuman Gene Therapy, 2003
- Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1Gene Therapy, 2002
- Inhibition of Angiogenesis by Adenovirus-Mediated sFlt-1 Expression in a Rat Model of Corneal NeovascularizationHuman Gene Therapy, 2001
- Alternative Splicing of Vascular Endothelial Growth Factor (VEGF)-R1 (FLT-1) pre-mRNA Is Important for the Regulation of VEGF ActivityMolecular Endocrinology, 1999
- Regional Suppression of Tumor Growth byIn VivoTransfer of a cDNA Encoding a Secreted Form of the Extracellular Domain of theflt-1Vascular Endothelial Growth Factor ReceptorHuman Gene Therapy, 1998
- Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDRBiochemical and Biophysical Research Communications, 1996
- Pathogenesis and InhibitionCornea, 1987